FDA Approves SetPoint Device for 1.5 Million U.S. Arthritis Patients After 242-Patient Trial
Updated
Updated · CNN · Jun 1
FDA Approves SetPoint Device for 1.5 Million U.S. Arthritis Patients After 242-Patient Trial
3 articles · Updated · CNN · Jun 1
The SetPoint System won FDA approval after a 242-patient randomized, double-blind trial showed the implanted device was safe and effective for rheumatoid arthritis patients who had exhausted standard treatments.
About the size of a multivitamin, the device is implanted on the vagus nerve in the neck and delivers a daily one-minute electrical stimulation to suppress harmful inflammation more consistently than drugs.
Rheumatoid arthritis affects about 1.5 million U.S. adults and 18 million people worldwide; existing treatments can lose effectiveness and carry side effects including infection risk from immune suppression.
Jessica Hancock, 49, said pain from more than a decade of rheumatoid arthritis disappeared after her October implant, and by January she no longer needed medication.
Roughly 30,000 patients sought spots in the trial, but inventor Kevin Tracey said insurers are now often denying coverage, setting up the next hurdle for wider adoption of the FDA-cleared therapy.
An FDA-approved implant can end arthritis suffering. Why are insurers blocking patients from getting it?
This tiny device could treat cancer and MS next. Will insurance battles stop the future of medicine?
Breakthrough in Rheumatoid Arthritis: FDA Approves SetPoint System, the First Bioelectronic Therapy for Inflammation Control
Overview
The FDA’s approval of the SetPoint System in August 2025 marked a major milestone in bioelectronic medicine, introducing the first non-drug medical treatment for rheumatoid arthritis. This surgically implanted device stimulates the vagus nerve to reduce inflammation through neuroimmune modulation, offering a new approach for patients who do not respond to traditional drugs. Supported by strong results from the RESET-RA study, the SetPoint System has shown significant and lasting improvements in disease activity and joint health. Now widely accessible across the US, it represents a significant shift away from conventional pharmacological treatments for chronic inflammatory conditions.